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The Inhalation Characteristics of Patients
When They Use Different Dry Powder Inhalers
Wahida Azouz, PhD,1 Philip Chetcuti, MB, ChB, FRCP,2 Harold S.R. Hosker, MB, ChB, FRCP,3
Dinesh Saralaya, MD, FRCP,4 John Stephenson, PhD,5 and Henry Chrystyn, PhD1
Abstract
Background: The characteristics of each inhalation maneuver when patients use dry powder inhalers (DPIs) are
important, because they control the quality of the emitted dose.
Methods: We have measured the inhalation profiles of asthmatic children [CHILD; n¼16, mean forced ex-
piratory volume in 1 sec (FEV1) 79% predicted], asthmatic adults (ADULT; n¼53, mean predicted FEV1 72%),
and chronic obstructive pulmonary disease (COPD; n¼29, mean predicted FEV1 42%) patients when they
inhaled through an Aerolizer, Diskus, Turbuhaler, and Easyhaler using their ‘‘real-life’’ DPI inhalation tech-
nique. These are low-, medium-, medium/high-, and high-resistance DPIs, respectively. The inhalation flow
against time was recorded to provide the peak inhalation flow (PIF; in L/min), the maximum pressure change
(DP; in kPa), acceleration rates (ACCEL; in kPa/sec), time to maximum inhalation, the length of each inhalation
(in sec), and the inhalation volume (IV; in liters) of each inhalation maneuver.
Results: PIF, DP, and ACCEL values were consistent with the order of the inhaler’s resistance. For each device, the
inhalation characteristics were in the order ADULT>COPD>CHILD for PIF, DP, and ACCEL (p<0.001). The
results showed a large variability in inhalation characteristics and demonstrate the advantages of DP and ACCEL
rather than PIFs. Overall inhaled volumes were low, and only one patient achieved an IV >4L and DP >4kPa.
Conclusion: The large variability of these inhalation characteristics and their range highlights that if inhalation
profiles were used with compendial in vitro dose emission measurements, then the results would provide useful
information about the dose patients inhale during routine use. The inhalation characteristics highlight that adults
with asthma have greater inspiratory capacity than patients with COPD, whereas children with asthma have the
lowest. The significance of the inhaled volume to empty doses from each device requires investigation.
Key words: inhaled therapy, dry powder inhalers, asthma, COPD, inhalation profiles
Introduction
Each dry powder inhaler (DPI) has its own uniquedose preparation and inhalation procedure, and many
patients have problems with this.(1) After a dose has been
prepared for inhalation, the formulation has to be deag-
gregated and dispersed into the conducting airstream inside
the device so that the emitted dose contains particles with the
likelihood for deposition in the airway. During each inhala-
tion, a turbulent energy is created inside the inhalation
channel, of each DPI, by the interaction between the patient’s
inhalation maneuver and the resistance inside the inhalation
channel of the DPI. This turbulent energy (which can be
measured as a pressure change) breaks up (deaggregates) the
formulation.(2)
To ensure adequate deaggregation, patients should use a
forceful and deep inhalation that begins from the start of their
inhalation.(3–5) It has been shown that the peak inhalation
flow (PIF) achieved by patients through each DPI is related
to clinical efficacy,(6–8) and some patients have problems
achieving a fast inhalation rate.(9) Asthmatic children(10) and
chronic obstructive pulmonary disease (COPD) patients(9)
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especially during acute exacerbations(11,12) are most likely
to have problems achieving sufficient turbulent energy inside
a DPI.
For each DPI, there is a minimum turbulent energy
threshold for sufficient deaggregation to occur during an
inhalation.(5) Hence, more attention needs to be directed to
the minimum acceptable PIF achieved through each DPI
rather than to the optimal flow. Also, it has been suggested
that the pressure changes that occur inside the inhala-
tion channel of each DPI(13) and the initial acceleration rate
of the inhalation maneuver(14,15) are more important than
PIF in the generation of the fine particle dose. Similarly,
inhaled volume is also considered an important parameter
of the inhalation profile and can govern the quality of the
emitted dose,(15) particularly in a capsule formulation(10,16)
because of the need to empty the capsule.
Information on the characteristics of an inhalation ma-
neuver when patients use different types of DPIs is limited.
The main aim of this study was to identify the inhalation
characteristics of different groups of patients (children with
asthma, asthmatic adults, and COPD patients) when they
inhaled through DPIs with a different resistance.
Materials and Methods
This was an open-label, single-visit study measuring in-
halation profiles of patients when they inhaled through four
different DPIs. Local research ethics approval (Yorkshire
and Humber REC: 09/H/1302/64) was obtained for this
study, and all participants gave signed informed consent.
For children, the parent/carer also gave consent.
Patients
Children with asthma (CHILD; aged 5 to 17 years), adults
with asthma (ADULT; aged 18 to 55 years), and those with
COPD (over 55 years of age) attending an outpatient ap-
pointment and prescribed a DPI for their inhaled medication
were eligible for inclusion. Those not eligible either had
been using a DPI for less than 4 weeks, were pregnant fe-
males, or had an acute exacerbation or were prescribed a
short course of oral prednisone in the past 4 weeks.
Measurement of inhalation characteristics
A Micro-Loop Spirometer (Cardinal Health, Swinden,
UK) was modified so that adapters could be fitted onto the
air inlet end of the spirometer. For each DPI, a specially
designed adapter was used to ensure airtight seals between
the adapter, the spirometer inlet, and the empty DPI. The
mouthpiece adapters were the same as those used for in vitro
dose emission measurements to insert an inhaler into the
USP induction port. Inhalation flow profiles were measured
by asking patients to make their normal (real-life) DPI in-
halation. The DPIs used were the Aerolizer (AERO;
Novartis, Basel, Switzerland), Diskus (DSK; GlaxoSmith-
Kline, Brentford, UK), Easyhaler (EASY; Orion, Espoo,
Finland), and the Turbuhaler (TBH; Symbicort version,
AstraZeneca, So¨derta¨lje, Sweden). Each device was the empty
placebo version. For the Diskus, the placebo version con-
taining the foil strips was used. As the blisters in this pla-
cebo device contain lactose, this was discharged before
each inhalation profile measurement. Also, the Aerolizer
contained a pierced empty capsule for each inhalation, be-
cause the resistance is lower without it.
The data from each inhalation flow profile was trans-
ported into Microsoft Access (Microsoft Corporation,
Redwood, WA) for data analysis. Flow rates were con-
verted into pressure changes using the resistance of the
DPI. The resistance of AERO, DSK, EASY, and TBH,
measured according to the method described by Clark and
Hollingworth,(2) was 0.0207, 0.0249, 0.0424, and 0.0335
(kPa)0.5(min L-1), respectively.
The inhalation characteristics obtained from each inha-
lation profile were the PIF (in L min–1), the time post start of
the inhalation when PIF occurred (Tp; in seconds), the
maximum pressure change that occurred inside the DPI (DP;
in kPa), the initial acceleration of the inhalation flow (AC-
CEL; in kPa sec - 1), the inhalation volume (IV; in liters),
and the duration of the inhalation (Ti; in seconds).
Study design
Each patient’s age, gender, height, and weight were re-
corded. Spirometry was measured using a ONEFLOW Spi-
rometer (Clement Clark International, Harlow, UK), and the
adults with asthma completed the Asthma Control Ques-
tionnaire (ACQ).(17)
The order of DPI used was randomized, and all patients
were instructed to make the same inhalation maneuver that
they made when using their DPI during routine use (no
training was given). The patient was seated when making the
measurements, because this was the most common position
that they all used. Each patient made two separate inhalations
through each device, and the profile with the fastest PIF was
chosen for data analysis. Patients were given a 5-min rest
between the two separate inhalations through each device
Data analysis
All analyses were performed using SPSS (Version 20.0;
IBM Corporation, Armonk, NY, USA). Demographic data
of patients in the three patient groups and outcome measures
obtained due to the use of all four devices were summarized
descriptively. A series of repeated-measures analyses of
variance (ANOVA) was carried out, considering each of the
six outcome measures in turn. Patient group was included
in all models as a between-subjects factor. Although some
evidence of a significant effect of age on certain outcome
measures was indicated, this variable was confounded with
patient group (as groups comprising adults and groups com-
prising children were both included in the study), and hence
was not included as a covariate. Further demographic vari-
ables did not indicate any relationship with the outcome
measures and were also not included. The Greenhouse-
Geisser correction factor was applied in cases of violation of
sphericity assumptions. In the case of significant findings,
post hoc tests were conducted to identify the source of any
significant differences between patient groups or device types
for any outcome measure. Sidak corrections for multiple
comparisons were applied as appropriate.
Results
Sixteen children with asthma, 53 adults with asthma,
and 29 patients with COPD completed all the inhalation
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maneuvers through the four DPIs. A summary of the de-
mographic data, lung function [presented as forced expi-
ratory volume in 1 sec (FEV1) % predicted], and disease
severity classification (according to GINA(18) and
GOLD(19) Guidelines) is presented in Table 1. The mean
(SD) ACQ of the 53 adults with asthma was 1.95 (1.01)
with only four indicating well-controlled asthma (ACQ
< 0.75), whereas 19 were classified as partly controlled
(0.75–1.5), and the remaining 30 poorly controlled (ACQ
> 1.5). All participants were using either a Diskus or a
Turbuhaler. Twelve of the children with asthma, 23 of the
adults, and 18 COPD patients were using a Diskus with the
remainder a Turbuhaler. Twenty-seven of the COPD
patients were also using a Handihaler.
The mean (SD) inhalation parameters of the inhalation
maneuvers through each DPI are presented in Table 2, and
the ranges of the PIFs, the pressure changes, and the inhaled
volumes are presented in the box plots in Figures 1, 2, and 3,
respectively. Table 2 shows that the acceleration rates of the
inhalation maneuvers were generally slower for the Diskus,
similar between the Aerolizer and Turbuhaler, and faster
through the Easyhaler (mean rates of 8.8, 10.6, 10.7, and
13.2 kPa sec - 1), respectively. Classification of patients with
respect to their PIF, the maximum pressure change, and their
inhaled volumes is shown in Table 3, and the relationships
between the inhaled volumes and the maximum pressure
changes is shown in Figure 4.
p values associated with each outcome measure arising
from repeated measures ANOVA mixed models, using pa-
tient group as a between-subject factor and device type as a
within-subject factor, are summarized in Table 4. There
were significant differences between the patient groups with
respect to the PIF, DP, ACCEL, and Tp outcome measures,
and significant differences between device types with re-
spect to the PIF, DP, and IV outcome measures.
Post hoc testing analysis of specific patient group com-
parisons, incorporating a Sidak correction for multiple
comparisons, indicated that with respect to the PIF and DP
outcome variables, adult and child asthmatic patients were
Table 1. Patient Details
CHILD ADULT COPD
Number (n) 16 53 29
Sex [M/F] (n) 13/3 11/42 15/14
Age in years 8.8 (3.08) 48.7 (16.03) 66.0 (9.6)
Height in cm 132.8 (20) 165.7 (9.67) 168.5 (10.2)
Weight in kg 34.8 (16.2) 75.5 (16.8) 78.0 (12.5)
FEV1 in liters 1.34 (0.67) 2.01 (0.62) 1.25 (0.8)
FEV1 %
predicted
78.5 (19.5) 72.0 (17) 41.5 (16.1)
PEF in L/min 182.8 (84.7) 301 (115.0) 173.3 (89.7)
PEF % predicted 65.1 (21.57) 71.8 (24) 44.9 (18.5)
FVC in liters 1.58 (0.73) 2.5 (0.8) 2.02 (0.6)
Disease severity (n)
Mild 8 17 12
Moderate 5 22 10
Severe 3 14 7
Very severe N/A N/A 0
All values are means (SD) unless indicated otherwise. FEV1, forced
expiratory volume; PEF, peak expiratory flow; FVC, forced vital
capacity.
Table 2. Mean (SD) Inhalation Parameters
AERO DSK TBH EASY
ALL PATIENTS
PIF (L min–1) 86.5 (26.3) 68.3 (25.0) 54.9 (17.3) 53.6 (15.2)
DP (kPa) 3.50 (2.07) 3.28 (2.24) 3.76 (2.29) 5.66 (3.11)
Tp (sec) 0.38 (0.19) 0.44 (0.22) 0.42 (0.17) 0.45 (0.16)
ACCEL (kPa sec–1) 10.6 (8.8) 8.8 (8.2) 10.7 (10.8) 13.2 (10.1)
IV (L) 1.77 (0.81) 1.71 (0.82) 1.49 (0.78) 1.52 (0.79)
Ti (sec) 1.61 (0.39) 1.56 (0.47) 1.59 (0.35) 1.60 (0.48)
CHILD
PIF (L min–1) 71.4 (21.5) 53.3 (24.2) 44.8 (16.0) 45.5 (13.2)
DP (kPa) 2.37 (1.33) 2.10 (1.70) 2.55 (1.79) 4.02 (2.21)
Tp (sec) 0.41 (0.13) 0.49 (0.19) 0.46 (0.20) 0.52 (0.18)
ACCEL (kPa sec–1) 7.2 (6.7) 5.4 (5.5) 6.7 (5.9) 8.9 (7.2)
IV (L) 1.22 (0.68) 1.19 (0.76) 1.00 (0.73) 1.00 (0.46)
Ti (sec) 1.69 (0.38) 1.50 (0.46) 1.52 (0.17) 1.62 (0.23)
ADULT
PIF (L min–1) 93.7 (25.9) 76.3 (23.8) 60.2 (17.0) 58.3 (14.4)
DP (kPa) 4.05 (2.19) 3.96 (2.39) 4.44 (2.39) 6.67 (2.28)
Tp (sec) 0.34 (0.14) 0.42 (0.25) 0.39 (0.14 0.43 (0.17)
ACCEL (kPa sec–1) 12.6 (9.8) 11.0 (8.8) 13.2 (13.0) 15.9 (11.5)
IV (L) 1.96 (0.77) 1.89 (0.74) 1.63 (0.74) 1.68 (0.81)
Ti (sec) 1.54 (0.34) 1.61 (0.56) 1.63 (0.45) 1.55 (0.47)
COPD
PIF (L min–1) 81.8 (25.4) 62.0 (22.4) 50.9 (15.3) 49.6 (15.0)
DP (kPa) 3.13 (1.88) 2.68 (1.80) 3.19 (1.94) 4.8 (2.71)
Tp (sec) 0.43 (0.28) 0.44 (0.16) 0.44 (0.20) 0.46 (0.14)
ACCEL (kPa sec–1) 8.7 (6.8) 6.7 (7.3) 8.5 (6.7) 10.7 (6.9)
IV (L) 1.71 (0.83) 1.79 (0.87) 1.50 (0.80) 1.52 (0.80)
Ti (sec) 1.71 (0.46) 1.53 (0.24) 1.57 (0.20) 1.68 (0.60)
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significantly different ( p < 0.001 for PIF; p = 0.003 for DP),
and the asthmatic children and the COPD patients were
significantly different ( p = 0.024 for PIF; p= 0.020 for DP);
however, the adult asthmatic and COPD patients were not
significantly different ( p = 0.469 for PIF; p = 0.629 for DP).
For the ACCEL outcome measure, analysis of specific pa-
tient group comparisons indicated a significant difference
between adult and child asthmatic patients ( p = 0.010), and
between the adult asthmatic and COPD patients ( p = 0.023),
but a nonsignificant difference between the children with
asthma and COPD patients ( p= 0.851). For the Tp outcome
measure, analysis of specific patient group comparisons
indicated a significant difference between the adult and
child asthmatic patients ( p = 0.028), but nonsignificant dif-
ferences between the adult asthmatics and the COPD pa-
tients ( p = 0.105), and between the children with asthma and
the COPD patients ( p = 0.780).
Analysis of specific device type comparisons, incorpo-
rating a Sidak correction for multiple comparisons, indi-
cated that for the PIF outcome variable, all devices were
significantly different from each other ( p < 0.001 in most
cases), except Turbuhaler and Easyhaler ( p = 0.955). For the
DP outcome variable, the Easyhaler device was significantly
different from all other devices ( p < 0.001 in all cases).
Additionally, the Turbuhaler device was significantly dif-
ferent from the Diskus device ( p = 0.006). No other pairs of
devices were significantly different from each other. For the
IV outcome measure, all devices were significantly different
from each other ( p< 0.001 in most cases), except the
Aerolizer and the Diskus ( p = 0.863) and the Turbuhaler and
the Easyhaler ( p= 0.633).
Due to the high correlations observed between the PIF,
DP, IV, and ACCEL variables, it was not considered ap-
propriate to apply any further corrections to the p values for
multiple comparisons.
Discussion
The results show that, as expected, adults with asthma
generate the most favorable inhalation maneuver character-
istics, and children with asthma the weakest, with COPD
patients slightly better than the children. The inhalation char-
acteristics between the DPIs were different, with the high-
resistance DPIs providing the most favorable set of inhalation
characteristics for formulation deaggregation and delivery of
FIG. 1. Peak inhalation flow (PIF) distributions from the
inhalation maneuvers through each DPI. The boxes repre-
sent the interquartile range with the median, and the whis-
kers represent the full range of the data (excluding the
outliers, which are shown as open circles).
FIG. 2. Maximum pressure change distributions, during
each inhalation maneuver through each DPI. The boxes
represent the interquartile range with the median, and the
whiskers represent the full range of the data (excluding the
outliers, which are shown as open circles).
FIG. 3. The inhaled volume distributions of each inhala-
tion maneuver through the DPIs. The boxes represent the
interquartile range with the median, and the whiskers rep-
resent the full range of the data (excluding the outliers,
which are shown as open circles).
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the emitted dose into the lungs. The results highlight that the
importance of these inhalation maneuver characteristics, re-
flecting real-life use when using a DPI, needs to be investi-
gated. The patients were not trained before the measurements,
and so the inhalation profiles are not maximum values.
Each inhaler was empty because any lactose in the air-
stream would have affected the measurements. This would
not alter the inhalation profile with a Turbuhaler. To our
knowledge, the presence of lactose does not affect a pa-
tient’s inhalation maneuver when using a DPI, and so any
affect on the inhalation profile for the other three inhalers
would be negligible. We measured inhalation profiles
without training so that real-life use data were obtained
rather than the maximum values each patient could achieve.
All participants were DPI users. Most COPD patients also
used the Handihaler, and so they would be familiar with
different levels of resistance between each type of DPI.
Traditionally, PIF has been the focus of attention when
patients use DPIs. However, this is only useful when
considering the flows through each DPI rather than com-
paring devices, because it is the generated turbulent energy,
which is a product of the flow and the resistance, that
deaggregates the formulation.(3,13) When the PIF was faster,
the turbulent flow generated in the inhalation channel of
Table 3. The Number of Patients Achieving Different Inhalation Flows Through Each DPI
CHILD ADULTS COPD
(a) Peak inhalation flow (L min–1)
< 30 30–59 60–89 > 90 < 30 30–59 60–89 > 90 < 30 30–59 60–89 > 90
AERO Nil 4 8 4 0 3 21 29 1 4 13 11
DSK 3 6 6 1 0 17 17 19 3 14 5 7
TBH 2 11 3 0 0 29 23 1 2 21 6 Nil
EASY 1 11 4 0 0 31 22 Nil 2 22 5 Nil
(b) Maximum pressure change (kPa)
< 1 1–1.99 2–3.99 > 4 < 1 1–1.99 2–3.99 > 4 < 1 1–1.99 2–3.99 > 4
AERO 3 5 5 3 2 7 18 26 2 8 11 8
DSK 6 6 1 3 0 13 16 24 3 9 9 8
TBH 2 5 6 3 0 9 20 24 2 7 14 6
EASY 1 1 8 6 0 0 15 38 1 3 9 16
(c) Inhaled volume (L)
< 1 1–1.99 2–3.99 > 4 < 1 1–1.99 2–3.99 > 4 < 1 1–1.99 2–3.99 > 4
AERO 8 6 2 0 8 18 28 0 5 17 6 1
DSK 8 6 2 0 6 22 25 0 2 19 7 1
TBH 9 6 1 0 13 22 18 0 7 17 5 0
EASY 9 7 0 0 15 19 19 0 8 17 3 1
FIG. 4. The relationship
between the inhaled volume
and the maximum pressure
change achieved by every pa-
tient when inhaling using each
of the DPIs (n= 98). (a) Aero-
lizer. (b) Diskus. (c) Easy-
haler. (d) Turbuhaler.
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each device was greater, thereby confirming why each DPI
has flow-dependent dose emission.(20) For each DPI, there
will be a minimum threshold turbulent energy (corresponding
to a measured pressure change) for efficient deaggregation
of the dose.(5) It has been shown that, below 30 L min - 1,
the turbulent energy generated inside a Turbuhaler is not
sufficient to efficiently deaggregate the dose,(21) and that
the clinical effect sharply decreases.(7) This flow is also
considered to be the minimum for the Diskus,(22) whereas
that for the Easyhaler is slightly lower,(23) but that for the
Aerolizer is much faster.(8)
Overall, the inhalation flows with the Turbuhaler are
higher than values previously reported in COPD,(24,25)
adults,(26) and children(7,27) with asthma, but lower than
others in COPD(28–30) and asthma.(29,31) The number of pa-
tients inhaling with an inhalation flow of < 30L min- 1
through the Turbuhaler is similar to that in other studies.(7,24,25,27)
When using the Diskus, similar numbers of COPD patients(25,29)
and children with asthma(22) achieved inhalation flow compared
with those in this study. This also applies to previous reports
of inhalation flows through the Easyhaler by children with
asthma(32) and COPD patients.(33)
The Aerolizer has low resistance, and so the minimum
flow for efficient deaggregation will be faster. It has been
reported that this flow could be > 90 L min - 1.(8) Table 3
shows that only 44 out of 98 participants achieved this
minimum flow, which is a lower proportion than previously
reported in adults and children with asthma.(34) This, to-
gether with the Diskus data (6 out of 98 inhaling < 30 L
min - 1), suggests that less efficient deaggregation occurs
with low-resistance DPIs. Also, when the flow is fast (due to
the lower resistance), there will be a tendency for more
oropharyngeal and central lung deposition. When using a
DPI, this is counterbalanced by the flow-dependent dose
emission from a DPI. However, dose emission from an
Aerolizer(35) and a Diskus(20) is less flow-dependent than
that from other DPIs. Hence, the low resistance of these
devices, together with the resultant fast inhalation flows,
will tend to provide low lung deposition and high oropha-
ryngeal impaction. Reduced peripheral lung deposition has
been reported when salbutamol was inhaled from a low-
resistance DPI.(36) In contrast, it has been shown that, when
using a Turbuhaler, which has pronounced flow-dependent
dose emission,(20) there is no change in the peripheral:cen-
tral lung deposition ratio when using faster flows.(37) Fur-
thermore, it has been reported that high-resistance DPIs do
provide greater lung deposition than those with a lower re-
sistance,(38) which could be related to the greater pressure
changes shown in Figure 2.
In contrast to PIF values, the pressure changes (hence the
turbulent energy) that occur inside each DPI during an in-
halation allow a comparison to be made between different
devices.(13) The results show that the pressure changes were
greater for the DPIs with a higher resistance than those with
a lower resistance, which explains why PIF measurements
should only be used to confirm that a patient can achieve the
threshold minimum flow for efficient deaggregation. Figure
2 shows that when the resistance is low-to-medium high
(Aerolizer, Diskus, and Turbuhaler), there is little difference
between the inhalers, and that for high-resistance inhalers
the pressure changes are much greater. This is due to the
nonlinear relationship between this pressure change with
flow and the resistance.(2)
The acceleration of the flow, like the pressure change, has
been shown to be critical for deaggregation of the formu-
lation in a DPI,(14,15) because the dose is emitted in the first
part of an inhalation. Overall, when the PIF was fast, then
the acceleration rates were steeper than when the PIF was
slow.(39) Previously, only the acceleration rates when asth-
matics and COPD patients inhaled through a Diskus and a
Turbuhaler have been reported.(29) Our results show that
acceleration rates were lower in children than in COPD
patients, whereas adults with asthma produced the steepest
rates.
The inhaled volume has two functions. First, the dose has
to be emptied from the device, and then the airstream de-
livers the particles into the airways. The inhaled volume
has to be sufficient for both to occur. Some DPIs require
a higher volume to empty the dose than others. It has
been reported that capsule-based DPI inhalers require 4 L
to completely empty their dose,(10,16) the Turbuhaler at least
1 L,(15) and the Diskus only 150mL.(15) These differences
are due to the design of the devices. Capsules have to be
emptied. The inhalation channel in the Turbuhaler is rela-
tively long and includes a cyclone, whereas the inhalation
channels of the Diskus and the Easyhaler are very short.(13)
Overall within the groups, the inhaled volumes were similar
for the different devices, with a tendency for a slightly larger
volume for DPIs with lower resistance. Table 3 shows that
many subjects could be using an inhaled volume that is too
small. Overall in COPD(29,30) and asthma(29,31) studies, the
volumes reported were higher than those in this study, but
one study using a Turbuhaler by adult asthmatics reported
similar volumes.(26) This difference, like those of the other
inhalation parameters, could be due to the amount of inha-
lation technique training that had previously been provided
to each patient.
Overall, the inhalation profiles indicate that the inhalation
volume could be more of a problem, and this has not pre-
viously been identified. Also, the pressure changes and the
acceleration of the inhalation maneuver should be consid-
ered. These parameters should replace the traditional focus
put on inhalation flow when using a DPI. The inhalation
volume results indicate that during training there should be
an emphasis that patients exhale before each inhalation
maneuver. Participants with low inhalation flow, suggesting
Table 4. P Values from Repeated Measures ANOVA Models: All Outcome Measures
p values from outcome measure
Variable PIF DP IV ACCEL Tp Ti
Patient group 0.001 0.001 0.094 0.001 0.013 0.871
Device type < 0.001 < 0.001 0.036 0.138 0.083 0.739
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that they need to use a more forceful inhalation through
their DPI, were retrained before they left the study. The
results in Table 3 highlight that it is the DPIs with low
resistance where retraining is important. The results also
suggest that the way forward could be to design DPIs with
high resistance.
Compendial methods recommend that dose emission and
the aerodynamic characteristics of the emitted dose should
be measured using a DP of 4 kPa and an inhaled volume of
4 L.(40,41) Figure 4 shows that only one patient achieved
these values. Furthermore, no individual replicated an in-
halation profile that was the same as a square wave produced
by a vacuum pump. Overall, the time of the PIF was 0.4–
0.5 sec, but some were up to 1.5 sec; hence, the shape of the
profiles was more sinusoidal. This highlights the need to
focus on using an inhalation that is as fast as possible from
the start when training patients how to use a DPI.(5) A
preliminary study has shown that the in vitro compendial
methods can be adapted, so that the square profile produced
by a vacuum pump can be replaced by inhalation profiles
like the real-life ones generated by the patients in this
study.(42) We have developed this methodology, and so stud-
ies with these inhalation profiles are ongoing. Dose emission
data using these profiles would provide the regulatory au-
thorities and others with information about the quality of the
dose patients would receive, and identify those that would
have problems generating an adequate dose during their in-
halation maneuver.
Conclusion
The results have provided an insight into the inhalation
maneuvers when patients use DPIs. As expected, the inha-
lation characteristics of children with asthma were lower
than those of adults and slightly less than those of COPD
patients. The importance of these inhalation maneuver
characteristics needs to be investigated with respect to the
dose that would have been emitted, as well as the likelihood
for lung deposition.
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